About 60 Degrees Pharmaceuticals
Connecting our passion for patients, science, and health with work that leaves an impact
OUR HISTORY AND MISSION
In 2010, 60 Degrees Pharmaceuticals began its mission to address vector-borne diseases through the development of innovative new treatments and preventive medicines. To this day, our mission continues.
OUR VALUES AND VISION
We value the needs of patients and providers in our approach to developing treatments that make a positive difference in people’s lives. With the successful launch of tafenoquine for malaria prevention, we are researching the utility of tafenoquine to address additional challenges in vector-borne diseases.
Our Team
Dr Geoffrey Dow is the CEO and president at 60 Degrees Pharmaceuticals, Inc., which he co-founded in 2010. He brings over 20 years of experience in tropical disease product development with a strong record of publications and patents. Dr Dow has 13 years of experience serving as a leader and advisor in the antimalarial drug development program at the Walter Reed Army Institute of Research and the US Army Medical Materiel Development Activity. He holds a BSc (Hons) and PhD in Veterinary and Biomedical Science from Murdoch University and an MBA from the University of Maryland.
Tyrone Miller is the Chief Financial Officer at 60 Degrees Pharmaceuticals, Inc. He joined the company in 2014 and has held various roles, advising in areas of financing and business planning. He is also the founder and principal of tax and accounting practice at Miller Tax & Advisory since 2011. Prior to that, he was a senior accountant at Sachs Figurelli, LLC from 2002 to 2011. He is a certified public accountant and received a Bachelor of Business Administration with a concentration in International Business from Emory University in 1996.
Dr Bryan Smith is the Chief Medical Officer at 60 Degrees Pharmaceuticals, Inc., with extensive expertise in clinical pharmacology, pharmacovigilance, regulatory strategy development, and translational medicine. He has over 30 years of experience in governmental research and leadership, and has served in several medical management and consulting roles. Joining the company in 2016, Dr Smith helps ensure compliance with laws and regulations, and oversees research and development projects. He is also a senior medical director of clinical and regulatory affairs at Fast-Track Drugs & Biologics, LLC. Dr Smith holds a Bachelor of Science in General Science, with highest honors, from Oregon State University and a Doctor of Medicine from Uniformed Services University of the Health Sciences.
Kristen Landon serves as Chief Commercial Officer, joining the company in 2024 with more than 29 years of experience building and transforming pharmaceutical brands across start-up and multinational organizations. She has launched and relaunched over a dozen brands across therapeutic areas, including women’s health, infectious disease, dermatology, nephrology, and hematology/oncology.
Most recently, she served as Senior Vice President of Marketing and Communications at TherapeuticsMD, where she led the branded portfolio, marketing insights, and corporate communications. She has also held senior leadership positions at companies such as Novartis and Abbott Laboratories.
Ms Landon holds an MBA from Silberman College of Business at Fairleigh Dickinson University and a bachelor’s degree from Kean University.
Directors
Cheryl Xu previously served as Biogen’s VP of Public Policy & Government Affairs. Previously, she ran a consulting business advising multinational companies on market access and expansion in China. She has also provided consultations to the US and Chinese governments on pharmaceutical policies, and was the Director of International Finance at Pharmacia. She holds a BS in Physics from Peking University and an MBA in Finance from Washington University.
Dr Stephen Toovey is an infectious and tropical disease physician. He specializes in influenza research and other respiratory viruses, malaria, rabies, and the neurological aspects of infectious diseases. Dr Toovey is CEO of Pegasus, a medical and scientific services company, and advises pharmaceutical companies and biotech organizations on infectious-disease–related matters. He has founded several pharmaceutical and adjacent companies, including co-founding Ark Biosciences in 2014, where he served as CMO until 2020. He currently teaches at the University College Medical School, is Deputy Editor of Travel Medicine and Infectious Disease, and has authored over 100 publications. Dr Toovey holds a PhD from the University of Ghent.
Paul Field has over 30 years of business development experience in the biopharmaceutical industry across a range of therapeutic areas. He is currently a corporate advisor at several companies, including Imunexus Ltd. and the Global Antibiotic R&D Partnership (Geneva). Previously, he was the life sciences specialist at the Australian government agency Austrade, where he facilitated foreign investment in Australian research on neglected tropical diseases, autoimmune diseases, cancer, and other programs. He has served on multiple boards of directors and is a Fellow of the Australian Institute of Company Directors.
Charles Allen has served as CEO and Chairman of BTCS Inc. since 2014, where he has been responsible for corporate strategy and direction. Mr Allen also serves as a director of Innovation1 Biotech Inc. He has extensive experience in business strategy, investment banking, and capital markets transactions, such as financing, initial public offerings, and mergers and acquisitions. Previously, Mr Allen was a managing director at various boutique investment banks and worked on domestic and international projects in technology, media, natural resources, logistics, medical services, and financial services. He holds a BS in Mechanical Engineering from Lehigh University and an MBA from the Mason School of Business at the College of William & Mary.
Eric Francois is a life sciences executive with over 25 years of experience, including 18 years as a senior banker with Raymond James, Credit Suisse, Lazard, and Cowen. He previously served as CFO and CBO of SCYNEXIS, a publicly traded anti-infectives company, where he raised over $300M and led business development activities. He also served as a director at Diffusion Pharma during its merger with EIP Pharma to form CervoMed. Mr Francois currently serves as a board member of CERo Therapeutics, an immunotherapy oncology company, providing strategic guidance on capital structure, business development, and transactions. He earned his MA in business and marketing from the Sorbonne University in France, where he also earned his BA in economics and business administration.
OPERATIONS
60 Degrees Pharmaceuticals is headquartered in Washington, DC (United States).
FORWARD LOOKING STATEMENTS. This communication includes forward-looking statements based on the Company’s current expectations and projections about future events. All statements contained in this communication other than statements of historical fact, including any statements regarding our future operations, are forward-looking statements. The words “believe”, “may”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “could”, “would”, “project”, “plan”, “potentially”, “likely” and similar expressions are intended to identify forward-looking statements as defined in the Private securities Litigation Reform Act of 1995. The forward-looking statements contained in this communication are based on knowledge of the environment in which the Company currently operates and are subject to changed based on various important factors that may affect the Company’s operations, growth strategies, financial results and cash flows, and as well as other factors beyond the Company’s control as of the date of this presentation. Important factors that could cause our actual results and financial conditions to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and otherwise provide for the commercialization of non-malaria prevention indications for Tafenoquine (Arakoda or other regimen) or Celgosivir/Australian Chestnut extracts in a timely manner, we may not be able to expand our business operations; we cannot guarantee our ability to conduct successful clinical trials; and we have no manufacturing capacity which poses the risk of lengthy and costly delays of bringing our products to market. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K and our subsequent Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at www.sec.gov. As a result of these matters, changes in fact, assumptions not being realized or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this presentation. In light of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements, which speak only as of the date of this presentation. Although we believe our expectations are based on reasonable assumptions, we can give no assurance that our expectations will materialize. Unless required by law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.